---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-002651"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:44:44.213981+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics elects Lisa Rometty to board of directors

## Summary
- Lisa Rometty elected director effective Jan 3, 2022; term expires at next annual meeting.
- Granted nonqualified stock options for 49,037 shares at $17.00 exercise price, vesting over 3 years.
- Compensation per standard non-employee director policy; standard indemnification agreement executed.
- No arrangement or understanding with others for election; no related-party transactions disclosed.

## SEC filing metadata
- accession: 0001193125-22-002651
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312522002651/0001193125-22-002651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312522002651/d281285d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-002651
- JSON: https://secwatch.observer/filing/0001193125-22-002651.json
- Plain text: https://secwatch.observer/filing/0001193125-22-002651.txt

## Key facts
- Executive change
  Lisa Rometty was elected as Director at Rani Therapeutics Holdings, Inc..
  - Action: elected
  - Role: Director
  source text: On January 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lisa Rometty as a director of the Company, effective January 3, 2022, with a term expiring at the Company’s next annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312522002651/0001193125-22-002651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.